Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St steadies ahead of South Korean chip bellwether SK Hynix's debut
- Oil heads for weekly gains as Middle East supply risks persist
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
Exelixis (EXEL) PT Bumped to $8 at Piper Jaffray, Remains Sidelined
August 4, 2016 7:21 AM EDTPiper Jaffray analyst Edward Tenthoff raised his price target on Exelixis (NASDAQ: EXEL) to $8.00 (from $5.00) but maintained a Neutral rating following results.
Tenthoff commented, "Exelixis reported COMETRIQ sales of $14M in 2Q:16 and CABOMETYX renal cell carcinoma (RCC) sales of $17.6M including... More
Exelixis (EXEL) Tops Q2 EPS by 11c, Revenue Tops Views
August 3, 2016 4:43 PM EDTExelixis (NASDAQ: EXEL) reported Q2 EPS of ($0.16), $0.11 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $36.3 million versus the consensus estimate of $17.96 million.
For earnings history and earnings-related data on Exelixis (EXEL) click here.
... More